Navigation Links
Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer

NEW YORK, April 10, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced that a Phase III study of ERBITUX(R) (Cetuximab) plus gemcitabine (a chemotherapy) in patients with locally advanced unresectable or metastatic pancreatic cancer did not meet its primary endpoint of improving overall survival.

Conducted by the Southwest Oncology Group (SWOG), a cancer center network sponsored by the National Cancer Institute, the open-label, randomized study compared ERBITUX plus gemcitabine to gemcitabine alone in more than 700 patients with pancreatic cancer in the first-line treatment setting. The study was conducted in centers throughout the United States and Canada. It was completed in a significantly shorter time than projected, providing a timely answer to an important research question. SWOG has informed ImClone and Bristol-Myers Squibb that the primary study endpoint of statistically improving overall survival was not met. The three parties -- SWOG, ImClone, and Bristol-Myers Squibb -- will engage in joint efforts to fully interpret these results.

"This study was designed to examine the Phase II results we previously observed for ERBITUX in patients with pancreatic cancer," stated Eric K. Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "We still consider pancreatic cancer to be of the utmost priority and we intend to pursue additional evaluations with ERBITUX including a pilot study of ERBITUX and bevacizumab with or without gemcitabine, as well as our pipeline agents, to improve the outcome for patients with pancreatic cancer."

"Pancreatic cancer is a devastating disease with few effective treatment options, and it is unfortunate that the use of ERBITUX in this trial has not demonstrated the benefit it has shown in other tumors," said Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affa
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
3. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/2/2014)... CARPINTERIA, Calif. , Sept. 2, 2014 ... assessments and penetration testing services, today released an IT ... industry. "Today,s healthcare CEOs are presiding over ... industry," said Daniel W. Berger , Redspin,s President ... help CEO,s and their Boards of Directors understand why ...
(Date:9/2/2014)... BEIJING , Sept. 2, 2014  Sinovac Biotech Ltd. ... products in China , today announced that ... in September: , Morgan Stanley Global Healthcare Conference, ... September 9 and 10, 2014. , Morgan Stanley Asia ... Hotel on September 11, 2014. , Aegis Healthcare & ...
(Date:9/2/2014)... Sept. 2, 2014  Drug delivery technologies that improve ... part of the entire drug development process. Pharmaceutical ... new vaccine delivery technologies in a bid to ... delivery procedures. New analysis from Frost ... the needle-free delivery sector currently makes up a ...
Breaking Medicine Technology:Sinovac to Participate in Upcoming Investor Conferences 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 3
(Date:9/2/2014)... (PRWEB) September 02, 2014 MyRounding, the ... care, has been selected from a group of over ... the 2014 PrIME Digital Health Challenge. The competition will ... another, Tuesday, Sept. 9th at the CSU Denver Atrium ... MyRounding is based in Denver, Colo. The cloud-based, SaaS ...
(Date:9/2/2014)... BESLER Consulting, a leading provider of Medicare ... to announce that it has released a special report ... 2015 Hospital Inpatient Prospective Payment System (IPPS) final rule ... Services. , “Hospitals are facing decreased Medicare reimbursements in ... BESLER’s President and Chief Executive Officer. “We are happy ...
(Date:9/2/2014)... September 02, 2014 “Is there an ... question that millions of people ask. Diagnosing and curing ... patients and their families or treatment partners. The diagnostic ... its distinct similarities to other skin conditions such as: ... bites, eczema, varicella and many others. Scabies is ...
(Date:9/2/2014)... 02, 2014 Michigan’s health care landscape ... Act and the Healthy Michigan Plan. Throughout these changes, ... a trusted funding resource for under-served individuals. Federal and ... or underinsured women between the ages of 50 and ... percent of the federal poverty level. , ...
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides many kinds ... employee internet monitoring products ( http://www.os-monitor.com ). Furthermore, the ... 10% off, on these useful items. , True ... different kinds of high end monitoring programs on its ... of all sizes. With its high end programs, the ...
Breaking Medicine News(10 mins):Health News:MyRounding Selected for Digital Health Venture Showcase Finals Top Three Startups Awarded $50,000 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 4Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 2Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 3Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2
... (sildenafil) can improve exercise capacity and functional ability in ... high pressure in the blood vessels that enter the ... report by Reuters, the findings, which appear in The ... study of 278 patients who were randomly selected to ...
... to stress during early life can lead to an ... adolescence.// It therefore, highlights the need for a counseling ... of growth. ,Several studies have established a ... with an increased risk of developing attachment disorders. These ...
... Death Syndrome (SIDS) has found out that nearly all cases ... a male sex hormone. //The levels are considerably higher in ... who have died suddenly from other causes. ,Researchers ... collected from 169 infants who had died of SIDS and ...
... findings were published by chemists at Harvard University, who ... they trigger could hold the key to oncogenesis,// the ... arises when an oncoprotien, a protein known to cause ... development of cancer, 'We present the hypothesis that an ...
... Research Institute have now found out that heart disease ... the thyroid gland.// Aggressive treatment of hypothyroidism and borderline ... diseases to a significant extent. ,The study has ... can be extrapolated to human beings as well. The ...
... of the National Cancer Institute conducted a meta-analysis of ... and the prevalence and associated mortality from colorectal cancer. ... of the Karolinska Institute in Stockholm, and colleagues. The ... at a 30 percent risk of developing colorectal cancer ...
Cached Medicine News:Health News:Teenage Mental Problems Could Be The Result Of Stress During Early Life 2Health News:Proper Treatment of Hypothyroidism Found To Prevent Heart Diseases 2
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Setting a new standard in protective apparel. The unique, patented Cool-Tech™ mesh-back design fits the natural contour of the body while reducing the amount of weight carried on the shoulders ...
Apron,special Proceddure...
Crisscross shoulder design facilitates better posture and distributes weight to back and hips for greater comfort. Shoulder pads soften shoulder contact with apron for additional comfort....
Medicine Products: